Skip to main content
MedPathMedPath Home
Clinical Trials/IRCT20090613002027N14
IRCT20090613002027N14
Completed
Phase 2

Evaluation of the efficacy and safety of adding olanzapine to the standard preventive regimen for chemotherapy- induced nausea and vomiting in children of 4-18 years of age, a Randomized Clinical Trial

Sari University of Medical Sciences0 sites49 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsPalliative care.Encounter for palliative care

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Palliative care.
Sponsor
Sari University of Medical Sciences
Enrollment
49
Status
Completed
Last Updated
7 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
7 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Sari University of Medical Sciences

Eligibility Criteria

Inclusion Criteria

  • •Cognitive abilities of 4 years old age
  • •Receiving chemotherapy medications with moderate to severe risk of emesis
  • •Age between 4 to 18 years old

Exclusion Criteria

  • •Brain tumor
  • •Receive of any anti psychotics 30 days before enrollment
  • •Inhibitors/Inducers of CYP1A2
  • •History of neuroleptic malignant syndrome
  • •History of seizure
  • •Sensitivity to olanzapine
  • •Cardiac arrhythmia
  • •History of uncontrolled diabetes mellitus

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Investigation of efficacy and safety of add-on therapy with DPP-4 inhibitor in type 2 diabetic patients poorly controlled with basal supported oral therapyType 2 diabetes
JPRN-UMIN000010849Department of Metabolism & Endocrinology Juntendo University Graduate School of Medicine40
Not yet recruiting
Phase 3
Effectiveness of Unani add-on therapy in preventing the disease severity of COVID-19 infectioHealth Condition 1: B972- Coronavirus as the cause of diseases classified elsewhereHealth Condition 2: J09- Influenza due to certain identified influenza viruses
CTRI/2020/12/029575Central Council for Research in Unani Medicine
Recruiting
Phase 2
Evaluation of the efficacy and safety of lacosamide to duloxetine in the treatment of taxanes- induced peripheral neuropathyTaxane-induced neuropathy.
IRCT20090613002027N21Mazandaran University of Medical Sciences60
Active, not recruiting
Not Applicable
A trial, in which subjects with type 2 diabetes, who qualify for treatment intensification, are given insulin degludec and, additionally, either liraglutide or insulin aspart, both in combination with metformin, with the largest meal. The purpose is to compare efficacy and safety of these two treatments.
EUCTR2011-001493-25-ATovo Nordisk A/S420
Active, not recruiting
Not Applicable
A trial, in which subjects with type 2 diabetes, who qualify for treatment intensification, are given insulin degludec and, additionally, either liraglutide or insulin aspart, both in combination with metformin, with the largest meal. The purpose is to compare efficacy and safety of these two treatments.Type 2 diabetesMedDRA version: 14.0Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersTherapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
EUCTR2011-001493-25-DEovo Nordisk A/S420